Skip to content

Biomarkers and rapid imaging in dementia diagnosis

Biomarkers & accelerate magnetic resonance imaging for dementia diagnosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN12777415
Enrollment
170
Registered
2024-02-21
Start date
2022-03-21
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia Mental and Behavioural Disorders

Interventions

170 participants from the cognitive disorders clinic at the National Hospital for Neurology and Neurosurgery (UCLH) will be recruited. These participants are due to have a same-day MRI scan which take

Sponsors

University of London
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. An individual with ability to engage in the decision to participate in the research study and provide informed consent 2. Aged 18 years old and above Main study: Patients attending the CDC at NHNN and at Darent Valley Hospital who are due to have a standard-of-care MRI of the brain as part of their routine investigation. Sub-study 1: Participants in other REC approved studies, who are scheduled for a planned MRI brain scan Sub-study 2: Healthy controls recruited through spouses/partners of patients, individuals who are included on the DRC Research Register and Join Dementia Research and patients attending the CDC at NHNN and at Darent Valley Hospital Sub-study 3: Participants recruited to the main study who are happy to be contacted about follow-up study procedures

Exclusion criteria

Exclusion criteria: 1. Unable to tolerate a routine MRI scan plus a 7-minute fast-MRI scan 2. Unable to tolerate draw blood by venepuncture

Design outcomes

Primary

MeasureTime frame
Non-inferiority of ultra-fast MRI compared to gold standard MRI assessed using a 5-point Likert scale at baseline

Secondary

MeasureTime frame
1. Stability of ultra-fast MRI compared to gold standard MRI, assessed using a 5-point Likert scale at 2 weeks to 2 months 2. Ability of ultra-fast MRI to track longitudinal change compared to gold standard MRI, assessed using a 5-point Likert scale at 1 year 3. Blood biomarkers assessed by immunoassays at baseline, 2 weeks to 2-month interval and 1-year interval

Countries

England, United Kingdom

Contacts

Public ContactMillie Beament
m.beament@ucl.ac.uk+44 (0)20 3448 4773

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Jun 27, 2026